Screener
Innoviva, Inc. INVA Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Gross Revenue From Contract With Customer Excluding Assessed Tax Before Amortization Of Capitalized Fees by Product | ||||||
| Long Acting Beta2Agonist Anoro | $12.14M-3.7% | $11.35M+9.4% | $11.47M-7.3% | $11.84M-3.8% | $12.6M-4.7% | |
| Long Acting Beta2Agonist Relvar Breo | $47.66M-12.9% | $47.28M-7.1% | $46.89M-12.5% | $51.51M+6.9% | $54.74M+1.4% | |
| Royalty | $59.79M-11.2% | $58.62M-4.3% | $58.35M-11.6% | $63.35M+4.7% | $67.34M+0.2% |
FAQ
- How does Innoviva, Inc. break its business down?
- Innoviva, Inc. (INVA) reports gross revenue from contract with customer excluding assessed tax before amortization of capitalized fees by product across 3 parts — Long Acting Beta2Agonist Anoro, Long Acting Beta2Agonist Relvar Breo and Royalty. Each is extracted from the segment footnotes and tracked over time.
- Where does Innoviva, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Innoviva, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
